KR20020086911A - 알츠하이머 질환과 관련된 신경정신적 행동의 치료를 위한갈란타민의 용도 - Google Patents
알츠하이머 질환과 관련된 신경정신적 행동의 치료를 위한갈란타민의 용도 Download PDFInfo
- Publication number
- KR20020086911A KR20020086911A KR1020027011063A KR20027011063A KR20020086911A KR 20020086911 A KR20020086911 A KR 20020086911A KR 1020027011063 A KR1020027011063 A KR 1020027011063A KR 20027011063 A KR20027011063 A KR 20027011063A KR 20020086911 A KR20020086911 A KR 20020086911A
- Authority
- KR
- South Korea
- Prior art keywords
- day
- galantamine
- weeks
- dose
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19425900P | 2000-04-03 | 2000-04-03 | |
| US60/194.259 | 2000-04-03 | ||
| PCT/EP2001/003553 WO2001074339A2 (en) | 2000-04-03 | 2001-03-28 | A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20020086911A true KR20020086911A (ko) | 2002-11-20 |
Family
ID=22716898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020027011063A KR20020086911A (ko) | 2000-04-03 | 2001-03-28 | 알츠하이머 질환과 관련된 신경정신적 행동의 치료를 위한갈란타민의 용도 |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1272192A2 (hu) |
| JP (1) | JP2003528913A (hu) |
| KR (1) | KR20020086911A (hu) |
| CN (1) | CN1430514A (hu) |
| AU (2) | AU6584401A (hu) |
| BG (1) | BG107093A (hu) |
| BR (1) | BR0109770A (hu) |
| CA (1) | CA2310926C (hu) |
| CZ (1) | CZ20023543A3 (hu) |
| EE (1) | EE200200554A (hu) |
| HR (1) | HRP20020778A2 (hu) |
| HU (1) | HUP0300566A3 (hu) |
| IL (1) | IL152061A0 (hu) |
| MX (1) | MXPA02009777A (hu) |
| NO (1) | NO20024746L (hu) |
| PL (1) | PL361272A1 (hu) |
| RU (1) | RU2002129298A (hu) |
| SK (1) | SK15422002A3 (hu) |
| WO (1) | WO2001074339A2 (hu) |
| ZA (1) | ZA200207935B (hu) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6617361B2 (en) * | 1999-11-05 | 2003-09-09 | Be Able, Llc | Behavior chemotherapy |
| EP1651234B1 (en) | 2003-07-25 | 2007-09-26 | F. Hoffmann-La Roche Ag | Combination of mglur2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders |
| DE10338544B4 (de) * | 2003-08-19 | 2017-08-31 | Janssen Pharmaceutica N.V. | Buccale Formulierungen des Galanthamins und deren Anwendungen |
| AU2009229372C1 (en) | 2008-03-27 | 2017-02-02 | Chase Pharmaceuticals Corporation | Use and composition for treating dementia |
| WO2013160728A1 (en) | 2012-04-26 | 2013-10-31 | Alma Mater Studiorum - Universita' Di Bologna | Dual targeting compounds for the treatment of alzheimer's disease |
| BG66818B1 (bg) * | 2013-03-07 | 2019-01-31 | Berbee Beheer B. V. | Състав на екстракт от hippeastrum papilio за производство на лекарствени средства и хранителни добавки |
| WO2016187339A1 (en) * | 2015-05-18 | 2016-11-24 | Synaptec Development Llc | GALANTAMINE CLEARANCE OF AMYLOIDß |
| CN117957003A (zh) * | 2021-09-09 | 2024-04-30 | 上海日馨医药科技股份有限公司 | 治疗神经退行性疾病的方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4663318A (en) * | 1986-01-15 | 1987-05-05 | Bonnie Davis | Method of treating Alzheimer's disease |
| DE19509663A1 (de) * | 1995-03-17 | 1996-09-19 | Lohmann Therapie Syst Lts | Verfahren zur Isolierung von Galanthamin |
| GB9600080D0 (en) * | 1996-01-04 | 1996-03-06 | Chiroscience Ltd | Resolution process |
| AU1738800A (en) | 1998-11-23 | 2000-06-13 | Bonnie Davis | Dosage formulations for acetylcholinesterase inhibitors |
| ES2211215T3 (es) * | 1998-12-24 | 2004-07-01 | Janssen Pharmaceutica N.V. | Composicion de galantamina de liberacion controlada. |
| CA2310990A1 (en) * | 2000-04-03 | 2000-10-09 | Michael Pontecorvo | A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease |
| CA2310950C (en) * | 2000-04-03 | 2005-11-08 | Janssen Pharmaceutica N.V. | An efficacious dosage regiment of galantamine that reduces side effects |
-
2000
- 2000-06-27 CA CA002310926A patent/CA2310926C/en not_active Expired - Lifetime
-
2001
- 2001-03-28 AU AU6584401A patent/AU6584401A/xx active Pending
- 2001-03-28 EE EEP200200554A patent/EE200200554A/xx unknown
- 2001-03-28 HU HU0300566A patent/HUP0300566A3/hu unknown
- 2001-03-28 CN CN01807334A patent/CN1430514A/zh active Pending
- 2001-03-28 PL PL36127201A patent/PL361272A1/xx not_active Application Discontinuation
- 2001-03-28 EP EP01943200A patent/EP1272192A2/en not_active Withdrawn
- 2001-03-28 JP JP2001572084A patent/JP2003528913A/ja not_active Withdrawn
- 2001-03-28 RU RU2002129298/14A patent/RU2002129298A/ru not_active Application Discontinuation
- 2001-03-28 BR BR0109770-9A patent/BR0109770A/pt not_active IP Right Cessation
- 2001-03-28 MX MXPA02009777A patent/MXPA02009777A/es unknown
- 2001-03-28 IL IL15206101A patent/IL152061A0/xx unknown
- 2001-03-28 WO PCT/EP2001/003553 patent/WO2001074339A2/en not_active Application Discontinuation
- 2001-03-28 CZ CZ20023543A patent/CZ20023543A3/cs unknown
- 2001-03-28 AU AU2001265844A patent/AU2001265844B2/en not_active Ceased
- 2001-03-28 KR KR1020027011063A patent/KR20020086911A/ko not_active Application Discontinuation
- 2001-03-28 SK SK1542-2002A patent/SK15422002A3/sk unknown
-
2002
- 2002-09-12 BG BG107093A patent/BG107093A/bg unknown
- 2002-09-26 HR HR20020778A patent/HRP20020778A2/xx not_active Application Discontinuation
- 2002-10-02 ZA ZA200207935A patent/ZA200207935B/en unknown
- 2002-10-02 NO NO20024746A patent/NO20024746L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EE200200554A (et) | 2004-04-15 |
| CA2310926A1 (en) | 2000-10-04 |
| PL361272A1 (en) | 2004-10-04 |
| AU2001265844B2 (en) | 2005-04-14 |
| BR0109770A (pt) | 2003-02-04 |
| SK15422002A3 (sk) | 2003-04-01 |
| HUP0300566A3 (en) | 2004-10-28 |
| AU6584401A (en) | 2001-10-15 |
| ZA200207935B (en) | 2004-01-30 |
| MXPA02009777A (es) | 2003-03-27 |
| CZ20023543A3 (cs) | 2003-03-12 |
| BG107093A (bg) | 2003-06-30 |
| IL152061A0 (en) | 2003-05-29 |
| HUP0300566A2 (hu) | 2003-06-28 |
| CN1430514A (zh) | 2003-07-16 |
| EP1272192A2 (en) | 2003-01-08 |
| CA2310926C (en) | 2002-10-15 |
| WO2001074339A3 (en) | 2002-09-12 |
| WO2001074339A2 (en) | 2001-10-11 |
| NO20024746L (no) | 2002-11-28 |
| RU2002129298A (ru) | 2004-03-27 |
| JP2003528913A (ja) | 2003-09-30 |
| HRP20020778A2 (en) | 2004-04-30 |
| NO20024746D0 (no) | 2002-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kuna et al. | Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double‐blind, parallel‐group study | |
| Malykh et al. | Piracetam and piracetam-like drugs | |
| Tancer et al. | The subjective effects of MDMA and mCPP in moderate MDMA users | |
| Amass et al. | Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine–naloxone tablet | |
| EP3010506B1 (en) | Pridopidine in treating huntington's disease | |
| CA2310950C (en) | An efficacious dosage regiment of galantamine that reduces side effects | |
| TW202110450A (zh) | 使用布魯頓酪胺酸激酶抑制劑治療慢性自發性蕁麻疹之方法 | |
| Casey et al. | Sulpiride in tardive dyskinesia | |
| KR20020086911A (ko) | 알츠하이머 질환과 관련된 신경정신적 행동의 치료를 위한갈란타민의 용도 | |
| JPH0667842B2 (ja) | 基本的うつ病を軽減するためのうつ病治療剤 | |
| JPH0920666A (ja) | 成熟遅延および類似疾患の治療用医薬組成物 | |
| Amore et al. | Long-term treatment of geropsychiatric depressed patients with venlafaxine | |
| US20120010242A1 (en) | Low dose pipamperone in treating mood disorders | |
| AU2001265844A1 (en) | A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease | |
| CN109069466A (zh) | 5-ht6受体拮抗剂用于治疗阿尔茨海默病伴情感淡漠共病 | |
| Dupont et al. | Oxatomide in the treatment of pruritus senilis: a double-blind placebo-controlled trial | |
| Rouillon et al. | Sulpiride in the treatment of somatoform disorders: results of a European observational study to characterize the responder profile | |
| US20060172993A1 (en) | Use of galantamine for the treatment of neuropsychiatric behaviour associated with Alzheimer's disease | |
| Van Bijsterveld et al. | Nedocromil sodium treats symptoms of perennial allergic conjunctivitis not fully controlled by sodium cromoglycate A double-masked placebo controlled group comparative study | |
| Marazziti | Venlafaxine treatment of obsessive-compulsive disorder | |
| Bullock et al. | Risperidone in the treatment of psychoses in the elderly: a case report series | |
| WO2014128882A1 (ja) | 不安うつ病の治療薬 | |
| Bennie et al. | Comparison of trazodone and mianserin in depressive illness | |
| Panas et al. | Belladonna alkaloids and phenobarbital use in the treatment of irritable bowel syndrome: a review | |
| Gerlach | Pharmacology and clinical properties of selective dopamine antagonists with focus on substituted benzamides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |